Pickle, thx for sharing that tidbit. This is what I posted here 2/10/17:
"Valuation models will start assigning higher probabilities of approval and the I foresee a rising share price between now and June, but we'll see."
Even if one is not inclined to hold all the way through to the PDUFA date, I think there is money to be made here while the analysts readjust their expectations. The current market cap puts a very low valuation on Betrixaban. Once the Adexanet filing is resubmitted, I think the overall picture clarifies and we will see the result reflected in share price. M&A is also picking up and there are big players who would see both products as complementary to their pipelines. Once the overseas funds are repatriated, big pharma will start spending.